Bone-specific alkaline phosphatase levels among patients with multiple myeloma receiving various therapy options Farkli Tedavi Rejimleri Alan Multipl Myelom Hastalarinda Kemik Spesifik Alkalen Fosfataz Düzeyleri
Turkish Journal of Hematology, cilt.31, sa.4, ss.374-380, 2014 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 4
- Basım Tarihi: 2014
- Doi Numarası: 10.4274/tjh.2013.0004
- Dergi Adı: Turkish Journal of Hematology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.374-380
- Anahtar Kelimeler: Multiple myeloma, Bone-specific alkaline phosphatase, Bortezomib, Thalidomide, BIOCHEMICAL MARKERS, KAPPA-B, BORTEZOMIB, DEXAMETHASONE, DISEASE, GROWTH, COMBINATION, THALIDOMIDE, PREDNISONE, METABOLISM
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
© 2015, Aves Yayincilik. All rights reserved.Objective: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels. Materials and Methods: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group). Results: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups. Conclusion: Considering that BALP is a surrogate marker of bone formation, our study suggests that bortezomib more efficiently leads to the improvement of bone disease in myeloma than other treatment options.